Mirae Asset Global Investments Co. Ltd. Buys 42,128 Shares of Gilead Sciences, Inc. $GILD

Mirae Asset Global Investments Co. Ltd. increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 556,766 shares of the biopharmaceutical company’s stock after buying an additional 42,128 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Gilead Sciences were worth $61,729,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of GILD. Smallwood Wealth Investment Management LLC bought a new stake in Gilead Sciences in the first quarter worth $25,000. Activest Wealth Management increased its stake in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the period. Goodman Advisory Group LLC purchased a new stake in Gilead Sciences in the first quarter worth $29,000. Colonial Trust Advisors increased its stake in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares during the period. Finally, Core Alternative Capital increased its stake in Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 241 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Price Performance

GILD opened at $110.56 on Friday. The business’s 50-day moving average is $114.42 and its two-hundred day moving average is $109.91. Gilead Sciences, Inc. has a 1 year low of $83.98 and a 1 year high of $121.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm has a market capitalization of $137.18 billion, a PE ratio of 22.02, a price-to-earnings-growth ratio of 0.76 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the firm earned $2.01 earnings per share. The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on GILD. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price on the stock in a research note on Tuesday, August 19th. UBS Group increased their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price on the stock in a research note on Friday, July 25th. Finally, Royal Bank Of Canada raised their price target on Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a research note on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $117.17.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the sale, the chief financial officer owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the sale, the insider directly owned 113,193 shares of the company’s stock, valued at approximately $12,855,329.01. This represents a 2.58% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 82,000 shares of company stock valued at $9,402,130. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.